Cancer Therapy

INGN 241 cancer therapy inhibits tumor angiogenesis

Published in Cancer Weekly, November 29th, 2005

Introgen Therapeutics, Inc. (INGN) reported data describing a novel mechanism of action by which its mda-7/IL 24 based therapy, INGN 241, inhibits the formation of new blood vessels, called angiogenesis.

In the absence of angiogenesis, tumors cannot establish a sufficient supply of oxygen and nutrients causing tumor cell death and inhibition of tumor growth. Introgen's studies demonstrate that INGN 241 acts as an antiangiogenic agent to inhibit production of a key mediator of angiogenesis called vascular endothelial growth factor (VEGF) protein.

These studies are published in Molecular Therapy and were conducted by researchers at Introgen and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-11-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry